Review Article
Ovarian Epithelial-Stromal Interactions: Role of Interleukins 1 and 6
Table 1
Proposed functions of IL-1 and IL-6 in OC.
| Cytokine | Inflammatory fnction | Proposed function in ovarian cancer | Model | Ref. |
| IL-1α | Proinflammatory | (i) Stimulate angiogenesis | (i) In vitro/In vivo | [27] | (ii) Recruit immunocompetent cells | (ii) In vitro/In vivo | [28–33] | (iii) Increase platelet count | (iii) Phase I clinical trial | [34, 35] |
| IL-1β | Proinflammatory | (i) Increase expression of MMP-1 | (i) In vitro | [36] | (ii) Stimulate production of proangiogenic factors | (ii) In vitro | [37] | (iii) Promote OC cell migration and invasion | (iii) In vitro | [38] |
| IL-1Ra | Anti-inflammatory | (i) Antagonist to IL-1α and IL-1β | | [39] | (ii) Abundant in the OC ascites | In vivo | [31, 40] |
| IL-6 | Anti-inflammatory | (i) Promote OC cell proliferation | (i) In vitro | [41] | (ii) Stimulate angiogenesis | (ii) In vitro/In vivo | [42] | (iii) Enhance endothelial cell migration | (iii) In vitro/In vivo | [42] | (iv) Increase OC cell lines capacity to secrete MMP-9 | (iv) In vitro | [43] | (v) Increase chemotactic and/or chemokinetic activity | (v) In vitro | [44] | (vi) Increase invasiveness | (vi) In vitro | [44] | (vii) Induce chemoresistance | (vii) In vitro/In vivo | [45–47] | (viii) Increase platelet count | (viii) Phase I and II clinical trial | [48, 49] |
|
|